World Health Organization Raises Concern Over Severe Scarcity of Weight-Loss Medications
Less than one in 10 individuals who could benefit from obesity jabs such as Wegovy can access them, warns the WHO as it releases its initial guidance on the medications.
With more than one billion individuals worldwide now obese, it is urging broader and more equitable access to these injectable treatments.
According to forecasts, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"Our latest guidelines recognises that obesity is a long-term condition that can be addressed with holistic and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and distribution challenges are major hurdles to broad access to the injections that can aid individuals in losing significant weight, notes the body.
Skinny Jab Shortage
Despite the present best projected outlook, the production of these medications might only reach around 100 million people – under 10% of those who need them, according to the health organization.
The advice urges countries and companies to increase availability, via approaches including patent sharing.
A patent on a key compound – the main ingredient of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Injections Function
These medications imitate a body's own hormone to reduce digestion speed, reduce hunger and boost satiety so individuals reduce food intake.
People usually see weight reduction in the initial weeks of beginning the once-weekly jabs.
Research points to people may regain a significant portion after a year of discontinuing the medication, as their typical hunger resume.
Being overweight or obese raises your risk for contracting medical conditions, such as type 2 diabetes, heart disease, brain attack, and specific cancers.
Excess weight affects individuals in countries worldwide and was responsible for millions of fatalities worldwide in 2024, according to the WHO.
